Moleculin Biotech Hosts Key Opinion Leaders Event

The latest update is out from Moleculin Biotech ( (MBRX) ).

On June 5, 2025, Moleculin Biotech, Inc. hosted a Virtual Soft Tissue Sarcoma (STS) Lung Mets Key Opinion Leaders event. The event featured compensated participation from key opinion leaders, Kasper and Cherry, highlighting the company’s focus on engaging expert insights in the field of soft tissue sarcoma, which could potentially impact its positioning and stakeholder relations in the biotech industry.

The most recent analyst rating on (MBRX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Average Trading Volume: 606,304

Technical Sentiment Signal: Sell

Current Market Cap: $11.87M

See more insights into MBRX stock on TipRanks’ Stock Analysis page.